Mary Ann Chirba
Mary Ann Chirba holds a bachelor's degree in biology from Colgate University and a J.D., magna cum laude, from Boston College Law School. She holds a Doctorate of Science in Health Policy and Law as well as a Master's in Public Health from the Harvard School of Public Health. She is the lead author of Health Care Reform: Law and Practice - A Comprehensive Guide to the Affordable Care Act and its Implementing Regulations, a 2 volume treatise, co-authored by Alice A. Noble (who also teaches at the Law School) and Michael M. Maddigan, and published by Lexis Nexis/Matthew Bender.
Since 1984, Professor Chirba has taught a variety of courses at Boston College Law School, including Law Practice I and II, Legal Reasoning Research & Writing, Federal Health Reform: The Affordable Care Act, Comparative Health Law, Health Care Law and Policy I & II, Advocacy Writing, Advanced Legal Writing, and Product Liability Law. She is a full Professor of Legal Reasoning and a member of the Law School’s health law faculty.
Professor Chirba holds a joint faculty appointment with the Tufts Medical School through its joint JD/MPH program with BC Law, and is an Adjunct Professor of Law at NYU Law School. She has lectured on a various health law issues at Harvard Medical School, Children's Hospital of Boston, and Brandeis University. In past years, Professor Chirba has been an adjunct faculty member at the Harvard School of Public Health, where she taught courses on Pharmaceutical Product Safety, Tobacco Regulation, Current Developments in Health Law, Managed Care Law & Regulation, and Medical Malpractice & Risk Management.
With Prof. Alice A. Noble, Dr. Chirba has published and spoken extensively on the Affordable Care Act. She has also published numerous articles and been invited to present at the World Stem Cell Summit and other domestic and international conferences on FDA and international regulation of adult stem cell therapies and regenerative medicine. Prof. Chirba serves as a member of the Advisory Boards of the International Federation of Adipose Therapeutics, the Cell Therapy Foundation, and the Leadership Education in Neuro-Developmental Disabilities (LEND) Fellowship program at Boston Children’s Hospital.